|
The Epidemiology of Infection with Vancomycin-Resistant Enterococci Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about The Epidemiology of Infection with Vancomycin-Resistant Enterococci conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. The Epidemiology of Infection with Vancomycin-Resistant Enterococci Clinical research trials and The Epidemiology of Infection with Vancomycin-Resistant Enterococci health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including The Epidemiology of Infection with Vancomycin-Resistant Enterococci. The Epidemiology of Infection with Vancomycin-Resistant Enterococci Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a The Epidemiology of Infection with Vancomycin-Resistant Enterococci clinical trial. Human subjects often get the best healthcare possible for their The Epidemiology of Infection with Vancomycin-Resistant Enterococci condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Epidemiology of Infection with Vancomycin-Resistant Enterococci  The Epidemiology of Infection with Vancomycin-Resistant Enterococci
The Epidemiology of Infection with Vancomycin-Resistant Enterococci
For Condition: Infection
Status: Recruiting
Sponsor(s): Department of Veterans Affairs Medical Research Service ,
Synopsis: Current projects study veteran patients with chronic ulcers and MRSA colonization and infection, patients with imipenem-resistant P. aeruginosa colonization and infection, the relationships between staffing pattern, severity of illness and nosocomial infections in intensive care units and infection control practices for veteran patients with suspected tuberculosis.
Details: Nosocomial infections are often caused by antimicrobial-resistant pathogens such as vancomycin resistant enterococci (VRE) and are a major cause increased morbidity, mortality and cost in hospitalized patients. Nosocomial bloodstream infections (BSI) add 7 to 21 days to the length of stay and cost institutions $3,061 to $40,000. The average cost of treating patients with VRE BSI has been estimated as 30% more than vancomycin sensitive enterococcal BSI. In addition, the attributable mortality of VRE BSI has been estimated as 37%. Preventing VRE infection and VRE transmission is clearly important and understanding the risk factors for each is a necessary first step. The goal of this three year study is to identify potentially effective interventions for the prevention of VRE infection and colonization Before testing interventions, we need to identify risk factors for VRE infection which will allow us to (1) identify potentially effective interventions and (2) focus on patients at highest risk for VRE infection. We will study the effect of antibiotic use, particularly vancomycin, and impaired host defenses on VRE infection in a large cohort study of VRE colonized patients. The goal is to develop a statistical model, which will allow us to identify alterable risk factors, which could reduce the risk of VRE infection. Many case-control studies have been performed to study VRE colonization and infection; however, most of these studies were small with insufficient sample sizes for multivariate modeling. Vancomycin-resistant enterococci (VRE) can be transmitted from patient to patient. We propose to model the ecological relationship between the rate of VRE transmission and the pre-existing prevalence of VRE in an ICU to determine whether the relationship is linear or exponential. The objective is to determine at what point the rate of transmission increases significantly that specific interventions should occur (e.g. reverse isolation of all patients, close unit to new admissions). Controlling health care costs is an important part of health care today and is particularly important in the capitated reimbursement system that VHA is adopting. Potential interventions to prevent VRE infections and VRE transmission must be cost-effective to the healthcare system to justify their adoption. The current study will quantify the operational costs associated with VRE colonization and infection in hospitalized patients compared to their non-colonized counterparts. Patients from the intensive care units with and without VRE colonization will be covaried for severity of illness and stratified by Major Diagnostic Category (by primary ICD-9 code) and marginal health care costs compared. This estimate can then be used to examine the potential cost-effectiveness of identified interventions, and to justify the system-wide costs of implementing these interventions.
Eligibility:
Study Type: Observational, Longitudinal, Defined Population, Prospective Study
Minimum Age/Maximum Age: 18 Years/90 Years
Genders: Both
Protocol Entry Criteria: Patients from the intensive care units with or without VRE colonization.
Total Enrollment:
Location and Contact Information:
VA Maryland Health Care System *Recruiting*
Baltimore, Maryland, 21201
United States
Recruiting Mary-Claire Roghmann 410-605-7394
Additional Information:
Study ID Numbers: CADE-RCD2;
Study Start Date: July 1998
Record last reviewed: June 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00018434
Other Infection Studies:
1. Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
2. Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter
3. A Safety Evaluation of Xigris in Patients with Blood Cancer who Develop Severe Infection related to Bone Marrow Transplantation.
4. Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia
5. Anidulafungin in Treating Immunocompromised Children With Neutropenia
Related Studies:
Other Infection Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials
The Epidemiology of Infection with Vancomycin-Resistant Enterococci
|
|
|
|
|
|
|
|
